Partisan Perspectives in the Medical Literature: A Study of High Frequency Editorialists Favoring Hormone Replacement Therapy

[1]  Marilyn J. Field,et al.  Conflict of Interest in Medical Research, Education, and Practice , 2009 .

[2]  C. Deangelis,et al.  Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. , 2009, JAMA.

[3]  J. Ioannidis,et al.  Persistent reservations against contradicted percutaneous coronary intervention indications: citation content analysis. , 2009, American heart journal.

[4]  C. Furberg,et al.  Why guideline-making requires reform. , 2009, JAMA.

[5]  J. Greene,et al.  A historical perspective of pharmaceutical promotion and physician education. , 2008, JAMA.

[6]  J. Ioannidis,et al.  Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? , 2008, Philosophy, ethics, and humanities in medicine : PEHM.

[7]  Harlan M Krumholz,et al.  Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. , 2008, JAMA.

[8]  R. Steinbrook.  Financial support of continuing medical education. , 2008, JAMA.

[9]  D. Rothman.  Academic medical centers and financial conflicts of interest. , 2008, JAMA.

[10]  E. Campbell,et al.  Responses of medical schools to institutional conflicts of interest. , 2008, JAMA.

[11]  P. Čičovački.  SOCIETY , 2008, Society.

[12]  A. Relman.  Medical professionalism in a commercialized health care market. , 2007, JAMA.

[13]  J. Ioannidis,et al.  Persistence of contradicted claims in the literature. , 2007, JAMA.

[14]  D. Grande.  A national survey of physician-industry relationships. , 2007, The New England journal of medicine.

[15]  D. Felson,et al.  Glucosamine for pain in osteoarthritis: why do trial results differ? , 2007, Arthritis and rheumatism.

[16]  Jane Green,et al.  Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005 , 2007, European Journal of Clinical Pharmacology.

[17]  E. Winer,et al.  Association between pharmaceutical involvement and outcomes in breast cancer clinical trials , 2007, Cancer.

[18]  Douglas G Altman,et al.  Ghost Authorship in Industry-Initiated Randomised Trials , 2007, PLoS medicine.

[19]  M. Chren,et al.  Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents , 2006, Annals of Internal Medicine.

[20]  Jordan J. Cohen,et al.  Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. , 2006, JAMA.

[21]  J. Ioannidis.  Why Most Published Research Findings Are False , 2005, PLoS medicine.

[22]  C. Wathen,et al.  Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care , 2004, Canadian Medical Association Journal.

[23]  Constance K Haan,et al.  Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[24]  R. Stafford,et al.  National use of postmenopausal hormone therapy: annual trends and response to recent evidence. , 2004, JAMA.

[25]  Mark Garton,et al.  Breast cancer and hormone-replacement therapy: the Million Women Study , 2003, The Lancet.

[26]  Valerie Beral,et al.  Breast cancer and hormone-replacement therapy in the Million Women Study , 2003, The Lancet.

[27]  D. Healy,et al.  Interface between authorship, industry and science in the domain of therapeutics , 2003, British Journal of Psychiatry.

[28]  Jeremy Spevick.  Financial conflicts of interest in biomedical research. , 2003, The virtual mentor : VM.

[29]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[30]  A. Detsky,et al.  Relationships between authors of clinical practice guidelines and the pharmaceutical industry. , 2002, JAMA.

[31]  L. Opie.  Conflict of interest in the debate over calcium-channel antagonists. , 1998, The New England journal of medicine.

[32]  C. Hammond.  Summary of balancing risks and benefits. , 2004, Obstetrics and gynecology.

[33]  M. Stefanick,et al.  Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society. , 2004, Menopause.

[34]  N. Blank.  Editorials and conflicts of interest. , 1997, The New England journal of medicine.